Induction of E-Cadherin in Lung Cancer and Interaction with Growth Suppression by Histone Deacetylase Inhibition

Jemal, 2006, Cancer statistics, 2006, CA Cancer J Clin, 56, 106, 10.3322/canjclin.56.2.106 Parkin, 2005, Global cancer statistics, 2002, CA Cancer J Clin, 55, 74, 10.3322/canjclin.55.2.74 Henschke, 2006, Survival of patients with stage I lung cancer detected on CT screening, N Engl J Med, 355, 1763, 10.1056/NEJMoa060476 Welch, 2007, Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study, Arch Intern Med, 167, 2289, 10.1001/archinte.167.21.2289 Sone, 2007, CT findings of early-stage small cell lung cancer in a low-dose CT screening programme, Lung Cancer, 56, 207, 10.1016/j.lungcan.2006.12.014 Sone, 2007, Long-term follow-up study of a population-based 1996–1998 mass screening programme for lung cancer using mobile low-dose spiral computed tomography, Lung Cancer, 58, 329, 10.1016/j.lungcan.2007.06.022 Roberts, 2007, Lung cancer screening with low-dose computed tomography: Canadian experience, Can Assoc Radiol J, 58, 225 Wilson, 2008, The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan, Am J Respir Crit Care Med, 178, 956, 10.1164/rccm.200802-336OC Cappuzzo, 2005, Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer, J Natl Cancer Inst, 97, 643, 10.1093/jnci/dji112 Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938 Cappuzzo, 2009, MYC and EIF3H coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib, J Thorac Oncol, 4, 472, 10.1097/JTO.0b013e31819a5767 Bremnes, 2002, High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer, J Clin Oncol, 20, 2417, 10.1200/JCO.2002.08.159 Hidaka, 1998, Expression of E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin in bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma: an immunohistochemical study, Mod Pathol, 11, 1039 Peinado, 2007, Snail, Zeb, and bHLH factors in tumour progression: an alliance against the epithelial phenotype?, Nat Rev Cancer, 7, 415, 10.1038/nrc2131 Witta, 2006, Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines, Cancer Res, 66, 944, 10.1158/0008-5472.CAN-05-1988 Ohira, 2003, WNT7a induces E-cadherin in lung cancer cells, Proc Natl Acad Sci USA, 100, 10429, 10.1073/pnas.1734137100 Clarhaut, 2009, ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells, Neoplasia, 11, 157, 10.1593/neo.81074 Qian, 2006, Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589, Clin Cancer Res, 12, 634, 10.1158/1078-0432.CCR-05-1132 Deroanne, 2002, Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling, Oncogene, 21, 427, 10.1038/sj.onc.1205108 Minucci, 2006, Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer, Nat Rev Cancer, 6, 38, 10.1038/nrc1779 Fotheringham, 2009, Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis, Cancer cell, 15, 57, 10.1016/j.ccr.2008.12.001 Zhu, 2003, The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells, Curr Med Chem Anticancer Agents, 3, 187, 10.2174/1568011033482440 Yu, 2007, Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation, Clin Cancer Res, 13, 1140, 10.1158/1078-0432.CCR-06-1751 Chang, 2002, Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung, Clin Cancer Res, 8, 1206 Ziauddin, 2006, Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation, Neoplasia, 8, 446, 10.1593/neo.05823 Hajji, 2008, Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells, Oncogene, 27, 3134, 10.1038/sj.onc.1210976 Ramalingam, 2007, Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies, Clin Cancer Res, 13, 3605, 10.1158/1078-0432.CCR-07-0162 Pauer, 2004, Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors, Cancer invest, 22, 886, 10.1081/CNV-200039852 George, 2005, Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3, Blood, 105, 1768, 10.1182/blood-2004-09-3413 Rao, 2008, HDAC6 inhibition enhances 17-AAG—mediated abrogation of hsp90 chaperone function in human leukemia cells, Blood, 112, 1886, 10.1182/blood-2008-03-143644 Scroggins, 2007, An acetylation site in the middle domain of Hsp90 regulates chaperone function, Mol cell, 25, 151, 10.1016/j.molcel.2006.12.008 Peart, 2005, Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors, Proc Natl Acad Sci USA, 102, 3697, 10.1073/pnas.0500369102 Handschuh, 1999, Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility, Oncogene, 18, 4301, 10.1038/sj.onc.1202790 Vandesompele, 2002, Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes, Genome biol, 3, 1, 10.1186/gb-2002-3-7-research0034 Chan, 2002, Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors, Clin Cancer Res, 8, 904 Kusy, 2005, Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells, Neoplasia, 7, 457, 10.1593/neo.04721 Gemmill, 2005, Synergistic growth inhibition by iressa and rapamycin is modulated by VHL mutations in renal cell carcinoma, Br J Cancer, 92, 2266, 10.1038/sj.bjc.6602646 Chou, 1984, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Adv Enzyme Regul, 22, 27, 10.1016/0065-2571(84)90007-4 Idziorek, 1995, YOPRO-1 permits cytofluorometric analysis of programmed cell death (apoptosis) without interfering with cell viability, J Immunol Methods, 185, 249, 10.1016/0022-1759(95)00172-7 Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 Miyanaga, 2008, Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model, Mol Cancer Ther, 7, 1923, 10.1158/1535-7163.MCT-07-2140 Chinnadurai, 2007, Transcriptional regulation by C-terminal binding proteins, Int J Biochem Cell Biol, 39, 1593, 10.1016/j.biocel.2007.01.025 Neckers, 2006, Using natural product inhibitors to validate Hsp90 as a molecular target in cancer, Curr Top Med Chem, 6, 1163, 10.2174/156802606777811979 Bohm, 1994, Differences of E-cadherin expression levels and patterns in primary and metastatic human lung cancer, Clin Exp Metastasis, 12, 55, 10.1007/BF01784334 Kase, 2000, Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance, Clin Cancer Res, 6, 4789 Liu, 2001, E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer, Ann Thorac Surg, 71, 949, 10.1016/S0003-4975(00)02545-5 Takeichi, 1991, Cadherin cell adhesion receptors as a morphogenetic regulator, Science, 251, 1451, 10.1126/science.2006419 Cowin, 2005, Cadherins and catenins in breast cancer, Curr Opin Cell Biol, 17, 499, 10.1016/j.ceb.2005.08.014 Khan, 2008, Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors, Biochem J, 409, 581, 10.1042/BJ20070779 Pruitt, 2006, Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation, PLoS Genetics, 2, e40, 10.1371/journal.pgen.0020040 van Grunsven, 2003, Interaction between Smad-interacting protein-1 and the corepressor C-terminal binding protein is dispensable for transcriptional repression of E-cadherin, J Biol Chem, 278, 26135, 10.1074/jbc.M300597200 Marks, 2007, Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug, Nat Biotechnol, 25, 84, 10.1038/nbt1272 Jaboin, 2002, MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors, Cancer Res, 62, 6108 Rosato, 2003, The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1, Cancer Res, 63, 3637 Lucas, 2004, The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells, Leukemia, 18, 1207, 10.1038/sj.leu.2403388 Dai, 2005, Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation, Mol Cell Biol, 25, 5429, 10.1128/MCB.25.13.5429-5444.2005 Wang, 2000, Paclitaxel-induced cell death: where the cell cycle and apoptosis come together, Cancer, 88, 2619, 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J